Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 26

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 26
---
 100 shares of our Common Stock. Brokerage commissions and other costs of transactions in odd -lotsare generally higher than the costs of transactions in “round -lots” of even multiples of 100 shares. After the Effective Time, we will continue to be subject to the periodic reporting and other requirements of the Exchange Act. Our Common Stock will continue to be traded on the OTC Pink Sheets under the symbol “CERO”. If a Reverse Stock Split is effected, then after the Effective Time, our Common Stock will have a new Committee on Uniform Securities Identification Procedures (“CUSIP”) number, which is a number used to identify our equity securities, and stock certificates for our Common Stock with the older CUSIP number will need to be exchanged for stock certificates with the new CUSIP number by following the procedures described above under “— Procedure for Implementing the Reverse Stock Split.” The Reverse Stock Split is not intended as, and will not have the effect of, a “going private transaction” as described by Rule 13e -3under the Exchange Act. After the Effective Time, the post -splitmarket price of our Common Stock may be less than the pre -splitprice multiplied by the reverse stock split ratio. In addition, a reduction in number of shares outstanding may impair the liquidity for our Common Stock, which may reduce the value of our Common Stock. In addition, a Reverse Stock Split would result in an increased proportion of unissued authorized shares to issued shares, which could have possible anti -takeovereffects and could be used by us to oppose a hostile takeover attempt or to delay or prevent changes in our control or management (for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Board or contemplating a tender offer or other transaction for the combination of us with another company). These authorized but unissued shares could (within the limits imposed by applicable law) be issued in one or more transactions that could make a change of control of the Company more difficult, and therefore more unlikely, or used to resist or frustrate a third -partytransaction that is favored by a majority of the independent stockholders. For example, without further stockholder approval, our Board could (within the limits imposed by applicable law) strategically sell shares of Common Stock in a private transaction to purchasers who would oppose a takeover or favor our then current Board, or the shares could be available for potential issuance pursuant to a shareholder rights plan. The additional authorized shares could be used to discourage persons from